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Abstract
AIM
To assess the safety and efficacy of transarterial 
chemoembolization (TACE) of hepatocellular carcinoma 
(HCC) using a new generation of 40 µm drug eluting 
beads in patients not eligible for curative treatment. 
METHODS
Drug eluting bead TACE (DEB-TACE) using a new generation 
of microspheres (embozene tandem, 40 µm) preloaded 
with 100 mg of doxorubicin was performed on 48 
early or intermediate HCC patients with compensated 
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cirrhosis. Response to therapy was assessed with Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) 
and modified RECIST (mRECIST) guidelines applied to 
computed tomography or magnetic resonance imaging. 
Eleven out of the 48 treated patients treated progressed 
on to receive liver orthotopic transplantation (OLT). This 
allowed for histological analysis on the treated explanted 
nodules.
RESULTS
DEB-TACE with 40 µm showed a good safety profile 
without major complications or 30-d mortality. The objec-
tive response rate of treated tumors was 72.6% and 
26.7% according to mRECIST and RECIST respectively. 
Histological examination in 11 patients assigned to OLT 
showed a necrosis degree > 90% in 78.6% of cases. 
The overall time to progression was 13 mo (11-21).
CONCLUSION
DEB-TACE with 40 µm particles is an effective treatment 
for the treatment of HCC in early-intermediate patients 
(Barcelona Clinic Liver Cancer stage A/B) with a good 
safety profile and good results in term of objective response 
rate and necrosis. 
Key words: Embozene tandem; Drug eluting beads; 
Drug eluting bead transarterial chemoembolization; 
Transarterial chemoembolization; Hepatocellular 
carcinoma 
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This is the first study exploring the safety 
and efficacy of 40 µm drug eluting bead transarterial 
chemoembolization for the treatment of hepatocellular 
carcinoma (HCC) in a series of 48 patients not suit-
able for ablation or surgical therapies. The use of 
microspheres smaller than 100 µm is not common 
practice in the western countries due to skepticism and 
fear of non-target embolization. Our aim is to present 
our initial experiences when treating with smaller 
microspheres so we all can test the potential advantages 
inherent to them and evaluate the effectiveness in the 
treatment of HCC nodules. 
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C, Vaiani M, Calareso G, Greco FG, Ragnanese A, Bongini 
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chemoembolization using 40 µm drug eluting beads for 
hepatocellular carcinoma. World J Radiol 2017; 9(5): 245­252 
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INTRODUCTION
Transarterial chemoembolization (TACE) is the current 
standard of care for hepatocellular carcinoma (HCC) 
in patients with multinodular disease, classified as 
intermediate stage (stage B) of the Barcelona Clinic Liver 
Cancer (BCLC) staging system[1]. Furthermore, in clinical 
practice, a number of patients with early stage (stage 
A) disease, not eligible for curative treatment (surgery, 
transplantation or ablation) are commonly treated with 
TACE[2,3]. 
Conventional TACE (c-TACE) has shown superiority 
over basic supportive care in unresectable HCC in two 
randomised studies published in the early 2000s[4,5] and 
in a meta-analysis published in 2003[6].
Recently developed drug eluting beads (DEB) have 
the ability to bind and carry up to double the doxorubicin 
dose[7,8] thus overcoming the common drawbacks of 
c-TACE such as the release of the chemotherapeutic agent 
into the systemic circulation. 
DEB-TACE superiority over c-TACE or TACE superiority 
over transarterial embolization has not been proven 
in recent studies[9,10] both in terms of survival and as 
objective response to treatment. These new micro-
spheres have ensured a reduction in the systemic 
concentration of the loaded chemotherapeutic agent, 
with a lower rate of post-procedural toxicity compared 
to c-TACE[11-13]. The first available microspheres had a 
diameter ranging between 500 and 900 µm that has 
gradually reduced over the years to let DEB penetrate 
deeper into tumor circulation arterioles. This theory is 
supported by recently published controlled studies on 
smaller microspheres that show encouraging preliminary 
data on the radiological response in terms of extensive 
intratumoral necrosis[14,15]. 
Embozene tandem 40 µm (Boston Scientific, Minne­
apolis, MA, United States) are a new size of tightly 
calibrated spherical drug-eluting beads able to load up 
100 mg of doxuribicin in a 2 mL syringe, or 150 mg in 
a 3 mL syringe. These biocompatible, non-resorbable, 
hydrogel microspheres are coated with an inorganic 
perfluorinated polymer (Polyzene®-F). They show a small 
increase in size (< 5% of the original diameter) during 
drug loading and storage if compared with similar DEB on 
the market. Dc­Beads M1 (initial diameter 70­150 µm) 
show a dehydration and loss in size after loading drug; 
Hepashere (initial diameter 30-60 µm), instead, show 
an increase in size up to 4 times of the initial diameter, 
resulting in a final diameter between 120­240 µm after 
loading drug. Smaller microspheres theoretically allow for 
more distal vascular penetration and more homogeneous 
intratumoral drug distribution, with no meaningful 
evidence of better results in terms of objective response 
if compared to 100-300 µm particles[16].
The aim of this study was to assess the efficacy 
and safety of 40 µm DEB-TACE in a series of 48 early-
intermediate HCC patients complying with eligibility criteria. 
Primary endpoint was the evaluation of adverse events and 
complications related to TACE as well as the tumor response 
rate, considered as best achieved response. Secondary 
outcomes were the time to progressions (TTP) and time to 
response (TTR).
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MATERIALS AND METHODS
Study population
Data from 48 early-intermediate HCC patients (BCLC 
stage A/B) referred to our two tertiary centers between 
May 2013 and May 2015 and treated with DEB­TACE 
using 40 µm microspheres were retrospectively analysed 
(Table 1). All patients signed a dedicated informed 
consent form. A multidisciplinary team made up of 
interventional radiologists, oncologists, hepatologists, 
pathologists and hepatic surgeons selected candidates 
for the treatment.
All patients were asymptomatic at enrolment (per-
formance status 0) with cirrhotic disease related to 
hepatitis C in 56.2% of cases (27/48). Fifty-six point 
two percent of patients were in BCLC B stage, while 
43.8% were in early stage A. All patients presented with 
a preserved liver function (93.4% Child­Pugh A and 
6.6% Child­Pugh B7). Other comorbidities were reported 
in approximately half of the study population (notably 
Diabetes, Arterial Hypertension and Chronic Obstructive 
Pulmonary Disease). No tumors receiving DEB­TACE had 
been previously treated. The mean number of tumors 
was 2 (range 1-4) with 30 mm (range 10-96) maximum 
mean diameter, and the mean sum of all maximum 
diameters came up to 44 mm (range 13-130).
Patient eligibility was established with the following 
inclusion criteria: Age > 18 years; HCC diagnosis according 
to the current guidelines[1-3]: Early/intermediate patients 
not eligible for percutaneous or surgical ablative therapies; 
well compensated cirrhosis with Child­Pugh Score up 
to B7; performance status 0 according to the Eastern 
Cooperative Oncology Group.
Exclusion criteria included bilirubin > 2 mg/dL; principal 
(main trunk) or segmental portal thrombosis; previous 
treatments on target tumors (ablation, TACE, Sorafenib); 
intolerance to doxorubicin (leukocyte count < 3000/
mm3; cardiac ejection fraction < 50%); aspartate amino 
transferase and alanine amino transferase levels > 270 
IU/mL, and patients receiving angiogenesis agents or 
affected by uncorrectable coagulation disorders.
Imaging study protocols
To assess the disease extent in the liver, its vascular 
pattern and possible intrahepatic vascular invasions, 
all patients received pre-treatment abdominal imaging 
with computed tomography (CT) 128 slices (Somaton 
Definition Flash, Siemens Healthcare, Erlangen, Germany) 
or with magnetic resonance imaging (MRI) 1.5 T (Achieva, 
Philips Healthcare, Best, the Netherlands). In addition to 
that, they received a CT scan of the chest for a complete 
staging of the extrahepatic disease.
CT image acquisition technique, before and after 
treatment, required both a baseline abdominal scan 
and the arterial, portal and late venous phase study 
after intravenous administration of a 120-140 mL bolus 
of iodinated contrast medium (Iopamiro 370 mg/dL, 
Bracco, Milan, Italy) at an injection flow of 4 mL/s with 
the Bolus Tracking technique.
The protocol for abdominal MRI required the acquisition 
of in-phase and out-of-phase T1 weighted sequences, T2 
weighted Half-Fourier acquisition Single-shot Turbo-spin 
Echo (HASTE) and Fat-Saturated (FAT-SAT) sequences, 
diffusion study and Tissue High Resolution Isotropic Voxel 
Excitation sequences [T1 weighted FAT­SAT and 3D GRE 
(3D GradientEcho)] both before and after infusion of 
Gadolinium­EthOxyBenzyl­Diethylene Triamine Pentaacetic 
Acid (Gd­EOB­DTPA) 0.025 mmol/mL (Primovist, Bayer, 
Leverkusen, Germany) with acquisitions up to 20 min 
during the hepatospecific phase.
DEB-TACE 
TACE was performed using transfemoral arterial access 
route with a micro-puncture system by placing a 5F 
vascular introducer (Boston Scientific, Natick, MA, United 
States). The angiographic study of the superior mesenteric 
artery and the celiac trunk for the characterisation of 
hepatic vascular anatomy was performed using an 
angiography unit (Axiom Angiographic Unit, Siemens 
Healthcare, Erlanger, Germany), and a 5F catheter 
(Cobra or Simmons, Boston Scientific, Natick, MA, 
United States). The angiographic study of extrahepatic 
pathological branches in some HCC tumors (usually 
peripheral tumors) was based on a careful study of pre-
TACE imaging or on missing parts of the pathological 
tumor vascularization at the selective angiographic study.
Selective studies of segmental and pathological 
feeding vessels were also performed using a coaxial 
A B
Figure 1  Patient with evidence of a ca. 32 mm tumor with arterial blood flow typical of hepatocellular carcinoma (wash-in phase at the centre of the image) 
in segment 3 treated with a  single cycle of transarterial chemoembolization. A: Corresponding histological image of the tumor after transplantation: Particles 
can be seen inside the afferent arterioles of the tumor, documenting 100% necrosis; B: The follow-up CT scan after TACE observed complete response according to 
mRECIST. TACE: Transarterial chemoembolization; mRECIST: Modified Response Evaluation Criteria in Solid Tumors; CT: Computed tomography.
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micro catheter (Progreat 2.7F, Terumo, Tokyo, Japan), 
with a highly selective administration of the treatment. 
In cases presenting multifocal disease, the treatment 
never targeted more than three hepatic segments 
per session. DEB-TACE was performed using a 2 mL/100 
mg of doxorubicin (Adriblastina, Pfizer, New York, NY, 
United States) loaded dose on embozene tandem 40 µm 
microspheres. 
In all performed DEB-TACE treatments embozene 
tandem 40 µm microspheres were diluted in 20-30 mL 
of iodinated contrast medium (Iopamiro 370 mg/dL), 
slowly injected manually with a 3 mL syringe, applying 
gentle pressure, until blood flow stasis was induced[17].
Vasodilator drugs via transcatheter intra-arterial were 
not administered before starting chemoembolization 
with a view to expand to the maximum the neoplastic 
vascular network and theoretically increase the pene-
tration of the particles and, accordingly, the potential 
effectiveness of the treatment as reported by some 
authors[18]. Permanent or temporary embolizing materials 
were not used to complete DEB-TACE in some tumors of 
greater dimensions where vascular stasis with only 40 
µm drug eluting beads was not achieved. In such cases, 
a second treatment session has been scheduled after 
performing a CT/MRI investigation to assess that some 
conditions leading to the impossibility of repeating the 
treatment, such as the onset of ascites or portal vein 
thrombosis, had not occurred.
Access haemostasis was achieved by a mechanical 
system, as Exoseal (Cordis, Miami Lakes, FL, United 
States), and a subsequent manual compression for about 
3-5 min until haemostasis was achieved.
Premedication included 100 mg of paracetamol 
(Paracetamolo 10 mg/mL S.A.L.F., Bergamo, Italy), 8 
mg of ondansetron (Ondansetron 8 mg/4 mL Hikma, 
Fervença, Portugal) and 50 mg of ranitidine (Ranitidina 
50 mg/5 mL, S.A.L.F., Bergamo, Italy). Intravenous 
antibiotic prophylaxis was administered with 2 g of 
cefazolin (Cefamizin, Pfizer, New York, NY, United States) 
consistent with the hospital internal guidelines.
Hospitalization, adverse events and toxicity
Patients were discharged after a brief observation 
period (48-72 h). Clinical evaluation and assessment 
of treatment-related toxicity were performed on an 
outpatient basis with physician’s visits and laboratory 
tests 12, 24 and 48 h after TACE, 4 wk later and every 
3 mo thereafter. AE were defined as treatment related 
if occurred during hospital stay or within 30 d from 
treatment. Safety parameters were classified according 
to the Common Terminology Criteria for Adverse Events 
4.0[19] at each follow-up visit. 
Imaging evaluation and follow-up
Two radiologists (Dr. Carlo Spreafico and Dr. Giorgio 
Greco) both experienced in interventional radiology and 
interventional hepatic imaging performed all radiological 
assessments independently. 
Tumoral response to treatment was assessed according 
to RECIST and mRECIST with a CT scan or MRI investi­
gation performed 4 wk after DEB-TACE and, then, every 
3 mo during the follow-up period[20].
A second treatment session, according to the “on 
demand” policy, was scheduled in case of partial response 
(PR) or stable disease (SD) after performing blood che­
mistry tests documenting good preserved hepatic function 
and continuity in the eligibility criteria for treatment. 
In case of repeated DEB-TACE sessions, only the 
best response was considered for analytical purposes 
since this has been recently proved a better predictor of 
survival than the initial response[21]. In patients submitted 
to OLT, the treated tumors were histologically analysed 
during the months after treatment with targeted definition 
of necrosis induced by TACE.
Statistical analysis 
The descriptive statistical analysis was expressed as 
median and range in the case of continuous variables 
and absolute numbers and percentage in the case of 
categorical ones. Time to best response and TTP were 
calculated with the Kaplan­Meyer method, computed 
from the time of the first treatment and censored to 
the day of transplantation in transplant patients. All 
calculations were obtained with the SPSS software (IBM, 
Armonk, NY, United States). The statistical review of the 
study was performed by a biomedical statistician.
RESULTS
DEB-TACE and radiological tumor response 
All procedures were performed without technical 
impediments that would prevent treatment of the 
target tumor. The two study sites performed an overall 
number of 73 TACE (47 segmental, 22 bisegmental and 
4 trisegmental) on a total number of 128 tumors. 31 
patients (64.7%) underwent one treatment cycle, 10 
patients (20.8%) to 2 treatment cycles, 6 patients (12.5%) 
to 3 treatment cycles, and 1 patient to 4 treatment cycles 
(2%), with a mean number of treatments per patient of 
1.45.
Response to treatment was assessed by classifying the 
tumors into three classes according to dimensional criteria, 
as specified in Table 2 (according to mRECIST) and Table 
3 (according to RECIST). The objective response rate (CR 
+ PR) was 26.8% and 69% for tumors smaller than 3 cm, 
32.1% and 85.7% for tumors with diameters between 3 
and 5 cm, 10% and 70% for tumors with diameter over 5 
cm according to RECIST and mRECIST, respectively. 
Considering all the treated tumors, the overall objective 
response rate (CR + PR) was 26.7% according to 
RECIST and 72.6% according to mRECIST. These data 
include all the 48 patients of our series. These results 
were calculated with RECIST and mRECIST criteria, 
based on the last available CT scan/MRI, with an overall 
mean follow-up period of 357 d (range 30-810). 
Hystological tumor response in transplanted patients
Eleven patients qualified for OLT after 15 overall cycles 
of DEB-TACE, with a mean number of treatments per 
Giorgio G et al . 40 µm DEB-TACE for hepatocellular carcinoma
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patient of 1.36. Seven out of 11 patients received 1 
treatment, with remaining 4 receiving 2 treatments. 
Median time elapsed between TACE and OLT was 4.8 mo 
(95%CI: 2.3-6.5). The histological examination (Table 
4) performed on 11 explanted livers reported a total 
number of 14 tumors of HCC, 10 of which were ≤ 3 cm 
and 4 were between 3 and 5 cm. 
Among the tumors smaller than 3 cm, 7 presented 
100% necrosis and 3 presented a necrosis rate below 
50%. Two out of 4 tumors > 3 cm presented a 100% 
necrosis rate (Figure 1), while the other 2 were above 
90%.
DEB-TACE: Adverse events and toxicity
Toxicity data are reported in Table 5. All the observed 
AE were mild and transient, with no grade 3/4 toxicity 
reported. There were no cases of post procedure mortality 
within 30 d. 
No major AE were recorded, neither systemically 
(pulmonary embolism, splenic infarction, gastrointestinal 
mucosal tumors, acute pancreatitis or cholecystitis, 
spinal cord injury) related to non-target embolization 
nor locally (hepatic infection or abscesses, ischemic 
hepatitis and bile duct injuries) due to local toxicity or 
ischemia[22]. Median hospital stay was 2 d (range 2­4). 
Post­embolization syndrome (PES) occurred in 15% of 
treatments (11/73). Other common AE were abdominal 
pain (24.6%) and nausea/vomiting (12.3%), which were 
treated with analgesic drugs and anti-emetics, and mild 
ascites (4.1%). Transient post procedure increase in 
transaminase levels occurred in 13.7% of cases (10/73). 
Other 1/2 grade laboratory tests alterations included a 
transient increase in bilirubin levels (6.8%). 
TTR, TTP and progression free survival 
The TTR for all patients was of 4 mo (95%CI: Range 1-4). 
Overall 24 patients (50%) experienced tumor progression 
through the study period. One­year progression free 
survival (PFS) was 64.5% whereas 2­year PFS was 52%. 
Median TTP was 13 mo (95%CI: Range: 11­21), calculated 
on mRECIST, as described in Figure 2.
DISCUSSION
DEB-TACE is the standard of care for HCC intermediate 
stage patients and a valuable therapeutic option in 
Age (yr)    67 (49-95)
Sex
   Male  42 (87.5)
   Female    6 (13.5)
Aetiology
   HCV  27 (56.2)
   HBV      9 (18.75)
   Alcohol    6 (12.5)
   Cryptogenetic      3 (6.25)
   NASH    3 (6.25)
Child-Pugh
   A  45 (93.4)
   B  3 (6.6)
MELD    8 (6-14)
BCLC
   A  21 (43.8)
   B  27 (56.2)
ECOG 0 48 (100)
Portal hypertension
   Yes   22 (45.9)
   No   26 (54.1)
Tumour extension
   Unilobar  29 (60.4)
   Bilobar  19 (39.6)
No. of tumors (target)
   Total  128
   Median  2 (1-4)
   Max. diameter (mm)    30 (10-96)
   Sum of diameters (mm)      44 (13-130)
TACE
   Total cycles 73
   Segmental 47 (64.4)
   Bisegmental 22 (30.1)
   Trisegmental 4  (5.5)
Table 1  Demographic characteristics and tumoral parameters 
of the study population,  n  (%)
TACE: Transarterial chemoembolization; HBV; Hepatitis B virus; HCV: 
Hepatitis C virus; NASH: Nonalcoholic steatohepatitis; MELD: Model 
for end-stage liver disease; BCLC: Barcelona Clinic Liver Cancer; ECOG: 
Eastern Cooperative Oncology Group.
Ø nodules No. of nodules CR PR SD PD
Ø < 3 cm   77 47.4% 21.6% 27.8% 3.2%
3 ≤ Ø ≤ 5 cm   22 42.8% 42.8% 10.8% 3.6%
Ø > 5 cm     3    40%    30%    30%    0%
Overall response 102    46% 26.6% 24.4%    3%
Table 2  Target lesions: Modified Response Evaluation Criteria 
in Solid Tumors response rate
CR: Complete response; PR: Partial response; SD: Stable disease; PD: 
Progressive disease.
Ø nodules No. of nodules CR PR SD PD
Ø < 3 cm   77 6.2% 20.6%    66% 7.2%
3 ≤ Ø ≤ 5 cm   22 3.5% 28.6% 64.4% 3.5%
Ø > 5 cm     3    0%    10%    90%    0%
Overall response 102 5.2% 21.5% 67.4% 5.9%
Table 3  Target lesions: Response Evaluation Criteria in Solid 
Tumors response rate
CR: Complete response; PR: Partial response; SD: Stable disease; PD: 
Progressive disease.
Ø nodules Degree of necrosis
100% > 90% < 50%
Ø < 3 cm 7 - 3
3 ≤ Ø ≤ 5 cm 2 2 -
Overall necrosis 9 (64.3%) 2 (14.3%) 3 (21.4%)
Table 4  Histological response rate of treated nodules in 
patients submitted to orthotopic transplantation
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BCLC A stage when curative approach is unfeasible[1,23]. 
Several consecutive sessions are usually needed for DEB-
TACE to be effective, i.e., the complete tumor response, 
so that the optimal treatment should lead to higher 
tumor necrosis rate with the lowest incidence of adverse 
event. DEB­TACE showed a low incidence of PES[13] 
and systemic toxicity than in previous reports[8], but its 
superiority over c-TACE is still a matter of debate[10,24-26].
Since the diameter of chemo loaded microspheres 
seems to be related to their therapeutic action[17,18], 
studies on pharmacological kinetics have focused on 
producing smaller particles that could penetrate deeper into 
the tumor’s vascular network. The most distal penetration 
of these microspheres reduces the phenomenon of 
hypoxic-ischaemic neoangiogenesis[27,28]. However, 
for embolization not associated with any drug (bland 
embolization), the use of particles with a diameter < 
100 µm presented a concerning rate of complications, 
especially in the treatment of large tumors[29,30]. Some 
complications in this type of procedures are related to the 
“non-target embolization” that is, the unwanted escape 
of microspheres outside the optimal area for treatment, 
which can affect other organs or unwanted areas of 
the same organ. Acute pancreatitis (0.88%-15.2%), 
acute cholecystitis (0.2%-5.4%), pulmonary embolism 
(0.17%-2.7%), splenic infarction (0.08%-1.4%), gastro-
intestinal mucosal tumors (0.22%-0.7%), spinal cord 
injury (0.3%-1.2%) are among the possible extrahepatic 
complications[31]. Unwanted hepatic complications such 
as ischemic hepatitis (0.26%-15.4%), liver infarction 
or abscess (0.5%-2.7%) or bile duct injuries[31] are 
connected to local ischemic damages. Some recent studies 
have proven a very high degree of safety in the use of 
loadable particles with diameters below 100 µm, with 
good preliminary efficacy results in terms of radiological 
and histological response to treatment[14,15,18].
A new generation of microspheres (embozene tandem 
40 µm) has been recently marketed for selective intra-
arterial treatment even though data on the efficacy and 
safety profile of the product is yet to be published. To 
our knowledge, this is the first report on the safety and 
efficacy of 40 µm particles preloaded with doxorubicin 
in the treatment of HCC with DEB-TACE. The overall 
objective response rate (CR + PR) obtained has been 
of 26.7% to RECIST and 72.6% to mRECIST. This is 
comparable to the rates according to mRECIST of two 
recent series carried out with 70-150 µm[14,15] and 30-60 
µm[18] (initial diameters) particles loaded with doxorubicin 
by Spreafico et al[14] and Malagari et al[18] respectively. 
Cases of failed response to locoregional therapy, 
defined as progressive disease, were around 5.9% and 
3% with RECIST and mRECIST, respectively. Median TTP 
was 13 mo (11-21), an interesting and slightly better 
result if compared with previous published trials using 
other microspheres. Moreover, it is to be considered 
that we did not restrict progression analysis only to 
local progression of target tumors, but also distant 
intrahepatic progressions and/or metastases occurrence 
were investigated. 
In 11 patients out of the recruited 48, DEB-TACE 
was used as bridging therapy for OLT with a complete 
pathologic response (meant as a 100% necrosis in the 
histological evaluation) in 64.3% cases (9/14 tumors). 
Tumors smaller than 3 cm shown a better response in 
term of histological necrosis (70% complete necrosis), 
compared to those larger than 3 cm (50% complete 
necrosis). These histological results are consistent with 
those reported elsewhere[32,33].
The best radiological response was obtained with 
a single cycle in 60% of patients, with two cycles in 
30% of cases and with three cycles in 10% of patients, 
with a TTR of about 4 mo (95%CI: Range: 4-6). The 
effectiveness of HCC treatment using TACE on demand 
has been proved in our series in the event of detection 
of SD or PR during the follow­up by CT or MRI, in line 
with data in the literature. The very low toxicity rates 
observed in our series are probably a consequence of the 
high selectivity of the procedure ensured by the use of 
smaller particles.
The procedures were generally well tolerated. 
Recorded toxicity levels were lower than recent studies 
using larger diameter microspheres and consistent with 
two other studies concerning microspheres with a pre-
loading diameter between 70-150 µm[14,15] and 30-60 µm[18].
The incidence of PES was to be lower than the per­
centages published in other series[11,12,14,18] with particles 
having similar or larger dimensions, most likely due to the 
selectivity of the procedure and possible sparing of a larger 
area of peritumoral hepatic parenchyma.
To our knowledge this is the first series regarding the 
use of 40 µm DEB in HCC treatment. This is interesting 
Toxicity Grade 1/2 Grade 3/4
Clinical findings
   Post embolization syndrome 11/73 (15%) -
   Ascites    3/73 (4.1%) -
   Abdominal pain    18/73 (24.6%) -
   Nausea/vomiting      9/73 (12.3%) -
Laboratory tests
   Bilirubin    5/73 (6.8%) -
   Transaminase    10/73 (13.7%) -
Table 5  Adverse events
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Figure 2  Time to progression.
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for world community and especially for western countries 
where there is skepticism about using particles smaller 
than 100 µm for DEB-TACE due to the non-target 
embolization danger. Our preliminary experience 
shows that 40 µm DEB-TACE is a highly effective and 
safe technique for HCC non suitable to ablation or 
surgery therapies with a low rate of PES and no major 
complications, either local or systemic. The results are 
complete for all the 48 patients and for 11 of them a 
histologically proven response to DEB-TACE on surgical 
specimen is available. Objective local response reached 
72.6% and 26.7% according to mRECIST and RECIST 
without damage to adjacent healthy liver as evidenced 
by imaging, histology and liver biochemistry. The study 
has some limitations such as the retrospective nature, 
the single series and the small sample of patients. 
Further studies with a longer follow-up period and a 
bigger sample should be planned to confirm our results. 
The results of this retrospective study indicate that 
DEB-TACE with 40 µm particles is an effective and safe 
treatment for early-intermediate HCC patients not 
eligible for curative treatment with good results in term 
of objective response rate and necrosis. 
COMMENTS
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Transarterial chemoembolization (TACE) is the current standard of care for 
hepatocellular carcinoma (HCC) in patients with multinodular disease, classified 
as intermediate stage (stage B) to Barcelona Clinic Liver Cancer (BCLC) Staging 
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of drug eluting bead TACE (DEB-TACE) on c-TACE or transarterial embolization in 
literature. In the last fifteen years many particles with diameters gradually smaller 
have been developed for DEB-TACE. These new 40 µm diameter drug eluting 
beads theoretically penetrate deeper into tumor circulation arterioles reducing 
the phenomenon of hypoxic-ischaemic neoangiogenesis due to transarterial 
embolization. There is no evidence in literature of DEB-TACE superiority over 
c-TACE in terms of efficacy. The only demonstrated vantage is the reduced rate 
of post embolic syndrome. 
Research frontiers
The authors’ report on 40 µm DEB-TACE for HCC is the first experience in 
literarature. The weakness points are the small sample of patients and the 
retrospective design of the study but it can represent an interesting report 
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generation of microparticles. Further studies with a larger number of patients 
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complications due to the phenomenon of non-target embolization, cause for 
concern in Western countries where the DEBTACE is widespread with larger 
gauge particles.
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This study suggests that 40 µm DEBTACE is safe and effective in early-
intermediate HCC patients with compensated cirrhosis. 
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escape of particles outside the territory seat of treatment.
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